Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse

Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders

Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870 · see citing works

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · see citing works

Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and <i>DSM-IV</i> Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions

Grant, B. F., Chou, S. P., Saha, T. D., Pickering, R. P., Kerridge, B. T., Ruan, W. J., Huang, B., Jung, J., Zhang, H., Fan, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2161 · Cited by 1,362 · see citing works

Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · see citing works

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · see citing works

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932 · see citing works

Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior

González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · see citing works

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706 · see citing works

Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior

Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 636 · see citing works

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · see citing works

Control of Dorsal Raphe Serotonergic Neurons by the Medial Prefrontal Cortex: Involvement of Serotonin-1A, GABA_A, and Glutamate Receptors

Celada, P., Puig, M. V., Casanovas, J. M., Guillazo, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09917.2001 · Cited by 497 · see citing works

Psychiatry &amp; the psychedelic drugs. Past, present &amp; future

Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343 · see citing works

REVIEW: The alcohol‐preferring P rat and animal models of excessive alcohol drinking

Bell, R. L., Rodd, Z. A., Lumeng, L., Murphy, J. M., & McBride, W. J. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2005.00029.x · Cited by 307 · see citing works

5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride

Vollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305 · see citing works

Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat

Spanagel, R., Hölter, S. M., Allingham, K., Landgraf, R., & Zieglgänsberger, W. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00174-4 · Cited by 277 · see citing works

Modern clinical research on LSD

Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236 · see citing works

A systematic study of microdosing psychedelics

Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235 · see citing works

Animal models of addiction

Spanagel, R. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.3/rspanagel · Cited by 224 · see citing works

In Vivo Modulation of the Activity of Pyramidal Neurons in the Rat Medial Prefrontal Cortex by 5-HT2A Receptors: Relationship to Thalamocortical Afferents

Puig, M. V. (2003) · Cerebral Cortex · doi:10.1093/cercor/13.8.870 · Cited by 223 · see citing works

Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression

Hibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00493 · Cited by 205 · see citing works

The alcohol deprivation effect model for studying relapse behavior: A comparison between rats and mice

Vengeliene, V., Bilbao, A., & Spanagel, R. (2014) · Alcohol · doi:10.1016/j.alcohol.2014.03.002 · Cited by 178 · see citing works

Addiction Research Consortium: Losing and regaining control over drug intake (ReCoDe)—From trajectories to mechanisms and interventions

Heinz, A., Kiefer, F., Smolka, M. N., Endraß, T., Beste, C., Beck, A., Liu, S., Genauck, A., Romund, L., Banaschewski, T., et al. (2019) · Addiction Biology · doi:10.1111/adb.12866 · Cited by 177 · see citing works

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers

Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5106-2 · Cited by 174 · see citing works

Effects of <i>N</i>,<i>N</i>-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression

Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171 · see citing works

Rescue of Infralimbic mGluR2Deficit Restores Control Over Drug-Seeking Behavior in Alcohol Dependence

Meinhardt, M. W., Hansson, A. C., Perreau‐Lenz, S., Bauder-Wenz, C., Stählin, O., Heilig, M. A., Harper, C. G., Drescher, K. U., Spanagel, R., & Sommer, W. H. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4062-12.2013 · Cited by 170 · see citing works

Chronic, Intermittent Microdoses of the Psychedelic <i>N</i> , <i>N</i> -Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents

Cameron, L. P., Benson, C. J., DeFelice, B. C., Fiehn, O., & Olson, D. E. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00692 · Cited by 168 · see citing works

Powerful substances in tiny amounts: An interview study of psychedelic microdosing

Johnstad, P. G. (2018) · Nordic Studies on Alcohol and Drugs · doi:10.1177/1455072517753339 · Cited by 155 · see citing works

The role of the NMDA receptor in alcohol relapse: a pharmacological mapping study using the alcohol deprivation effect

Vengeliene, V., Bachteler, D., Danysz, W., & Spanagel, R. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.01.002 · Cited by 139 · see citing works

Long-term ethanol self-administration with repeated ethanol deprivation episodes changes ethanol drinking pattern and increases anxiety-related behaviour during ethanol deprivation in rats.

Hölter, S. M., Engelmann, M., Kirschke, C. P., Liebsch, G., Landgraf, R., & Spanagel, R. (1998) · PubMed · Cited by 127 · see citing works

Microdosing psychedelics: Motivations, subjective effects and harm reduction

Lea, T., Amada, N. M., Jungaberle, H., Schecke, H., & Klein, M. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.11.008 · Cited by 121 · see citing works

Psychedelic microdosing: a subreddit analysis

Lea, T., Amada, N., & Jungaberle, H. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1683260 · Cited by 115 · see citing works

Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats

Hölter, S. M., & Spanagel, R. (1999) · Psychopharmacology · doi:10.1007/s002130051069 · Cited by 114 · see citing works

Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms

dos Santos, R. G., & Hallak, J. E. C. (2020) · Neuroscience &amp; Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.001 · Cited by 111 · see citing works

RESEARCH FOCUS ON COMPULSIVE BEHAVIOUR IN ANIMALS: Compulsive alcohol drinking in rodents

Vengeliene, V., Célèrier, E., Chaskiel, L., Penzo, F., & Spanagel, R. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00177.x · Cited by 103 · see citing works

Pyramidal Neurons in Rat Prefrontal Cortex Projecting to Ventral Tegmental Area and Dorsal Raphe Nucleus Express 5-HT2A Receptors

Vázquez, P. M., Cortés, R., & Artigas, F. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhn204 · Cited by 102 · see citing works

Kappa-opioid receptors and relapse-like drinking in long-term ethanol-experienced rats

Hölter, S. M., Henniger, M. S. H., Lipkowski, A. W., & Spanagel, R. (2000) · Psychopharmacology · doi:10.1007/s002130000601 · Cited by 100 · see citing works

A Controlled Study of Lysergide in the Treatment of Alcoholism. I . The Effects on Drinking Behavior

Smart, R. G., Storm, T., Baker, E. F. W., & Solursh, L. P. (1966) · Quarterly Journal of Studies on Alcohol · doi:10.15288/qjsa.1966.27.469 · Cited by 100 · see citing works

Why we should consider sex (and study sex differences) in addiction research

Sanchis‐Segura, C., & Becker, J. B. (2016) · Addiction Biology · doi:10.1111/adb.12382 · Cited by 90 · see citing works

Postdependent state in rats as a model for medication development in alcoholism

Meinhardt, M. W., & Sommer, W. H. (2014) · Addiction Biology · doi:10.1111/adb.12187 · Cited by 83 · see citing works

New Pharmacological Treatment Strategies for Relapse Prevention

Spanagel, R., & Vengeliene, V. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_205 · Cited by 80 · see citing works

Glycine Transporter-1 Blockade Leads to Persistently Reduced Relapse-like Alcohol Drinking in Rats

Vengeliene, V., Leonardi‐Essmann, F., Sommer, W. H., Marston, H. M., & Spanagel, R. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.029 · Cited by 76 · see citing works

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities

Rosenbaum, D., Weissman, C., Anderson, T., Petranker, R., Dinh-Williams, L.-A., Hui, K., & Hapke, E. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120908004 · Cited by 76 · see citing works

Intranasal delivery of mesenchymal stem cell‐derived exosomes reduces oxidative stress and markedly inhibits ethanol consumption and post‐deprivation relapse drinking.

Ezquer, F. E., Quintanilla, M. E., Morales, P., Santapau, D., Ezquer, M., Kogan, M. J., Salas‐Huenuleo, E., Herrera‐Marschitz, M., & Israel, Y. (2018) · Addiction Biology · doi:10.1111/adb.12675 · Cited by 65 · see citing works

Paradoxical role of an Egr transcription factor family member, Egr2/Krox20, in learning and memory

Poirier, R. (2007) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.006.2007 · Cited by 64 · see citing works

Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat

Jefsen, O. H., Højgaard, K., Christiansen, S. L., Elfving, B., Nutt, D., Wegener, G., & Müller, H. K. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.15 · Cited by 63 · see citing works

Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models

Yardley, M. M., & Ray, L. A. (2016) · Addiction Biology · doi:10.1111/adb.12349 · Cited by 60 · see citing works

New Pharmacological Treatment Strategies for Relapse Prevention

Spanagel, R., & Vengeliene, V. (2012) · Current topics in behavioral neurosciences · doi:10.1007/978-3-642-28720-6_205 · Cited by 56 · see citing works

Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats

Horsley, R. R., Páleníček, T., Kolin, J., & Valeš, K. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000394 · Cited by 52 · see citing works

Studying the Effects of Classic Hallucinogens in the treatment of alcoholism: Rationale, methodology, and current research with psilocybin

Bogenschutz, M. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990002 · Cited by 47 · see citing works

LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice

Alper, K., Dong, B., Shah, R., Sershen, H., & Vinod, K. Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00994 · Cited by 38 · see citing works

Advances in Pharmacotherapy Development: Human Clinical Studies

Litten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_79 · Cited by 29 · see citing works

Psilocybin: Biphasic dose-response effects on the acoustic startle reflex in the rat

Davis, M. T., & Walters, J. K. (1977) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(77)90180-0 · Cited by 26 · see citing works

Psilocybin as a discriminative stimulus: Lack of specificity in an animal behavior model for ?hallucinogens?

Koerner, J., & Appel, J. B. (1982) · Psychopharmacology · doi:10.1007/bf00435266 · Cited by 19 · see citing works

High hopes

Kupferschmidt, K. (2014) · Science · doi:10.1126/science.345.6192.18 · Cited by 19 · see citing works

The Calpain Inhibitor A-705253 Attenuates Alcohol-Seeking and Relapse with Low Side-Effect Profile

Vengeliene, V., Möller, A., Meinhardt, M. W., Beardsley, P. M., Sommer, W. H., Spanagel, R., & Bespalov, A. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.225 · Cited by 12 · see citing works

Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism

Meinhardt, M. W., Pfarr, S., Fouquet, G., Rohleder, C., Meinhardt, M. L., Barroso-Flores, J., Hoffmann, R., Jeanblanc, J., Paul, E., Wagner, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2399 · Cited by 89 · see citing works

Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy

Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73 · see citing works

Therapeutic mechanisms of psychedelics and entactogens

Heifets, B., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 64 · see citing works

Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property

Higgins, G. A., Carroll, N. K., Brown, M., MacMillan, C., Silenieks, L. B., Thevarkunnel, S., Izhakova, J., Magomedova, L., DeLannoy, I., & Sellers, E. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640241 · Cited by 70 · see citing works

Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective

Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69 · see citing works

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103149 · Cited by 61 · see citing works

Potential Differences in Psychedelic Actions Based on Biological Sex

Shadani, S., Conn, K., Andrews, Z. B., & Foldi, C. J. (2024) · Endocrinology · doi:10.1210/endocr/bqae083 · Cited by 60 · see citing works

Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research

Mendes, F. R., Costa, C. D. S., Wiltenburg, V. D., Morales-Lima, G., Fernandes, J. A. B., & Filev, R. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100025 · Cited by 59 · see citing works

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies

Calleja‐Conde, J., Morales-Garcia, J. A., Echeverry‐Alzate, V., Bühler, K., Giné, E., & López‐Moreno, J. A. (2022) · Addiction Biology · doi:10.1111/adb.13229 · Cited by 54 · see citing works

Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice

Jones, N., Zahid, Z., Grady, S. M., Sultan, Z. W., Zheng, Z., Razidlo, J. A., Banks, M. I., & Wenthur, C. J. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00123 · Cited by 50 · see citing works

Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice

Fadahunsi, N., Lund, J. T., Breum, A. W., Mathiesen, C. V., Larsen, I. B., Knudsen, G. M., Klein, A. B., & Clemmensen, C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02103-9 · Cited by 47 · see citing works

Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016–2020) systematic review of preclinical and human studies

Rodrigues, L. S., Rossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01267-7 · Cited by 46 · see citing works

Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice

Alper, K., Cange, J., Sah, R., Schreiber-Gregory, D., Sershen, H. W., & Vinod, K. Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1074633 · Cited by 40 · see citing works

Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders

Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 34 · see citing works

Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats

Floris, G., Dabrowski, K. R., Zanda, M. T., & Daws, S. E. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02788-y · Cited by 30 · see citing works

Animal Behavior in Psychedelic Research

Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000590 · Cited by 28 · see citing works

The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals

Campbell, E. J., Bonomo, Y. A., Pastor, A., Collins, L., Norman, A. F., Galettis, P., Johnstone, J., & Lawrence, A. J. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.767 · Cited by 27 · see citing works

Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats

Reinwald, J., Schmitz, C. N., Skorodumov, I., Kuchař, M., Weber‐Fahr, W., Spanagel, R., & Meinhardt, M. W. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02690-1 · Cited by 25 · see citing works

A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder

Celik, M., Gold, M. S., & Fuehrlein, B. (2024) · Brain Sciences · doi:10.3390/brainsci14030294 · Cited by 25 · see citing works

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review

Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 23 · see citing works

Psychedelics: Science sabotaged by Social Media

Sellers, E. M., & Romach, M. K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109426 · Cited by 22 · see citing works

Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity

Huang, J. Y., Pham, M. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.891512 · Cited by 20 · see citing works

Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice

Elsilä, L. V., Harkki, J., Enberg, E., Martti, A., Linden, A.-M., & Korpi, E. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221104641 · Cited by 19 · see citing works

Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin

Gattuso, J. J., Wilson, C., Li, S., Hannan, A. J., & Renoir, T. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177304 · Cited by 18 · see citing works

Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories

Benvenuti, F., Colombo, D., Soverchia, L., Cannella, N., Domi, E., & Ciccocioppo, R. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06384-w · Cited by 18 · see citing works

Psychedelic science in post-COVID-19 psychiatry

Kelly, J. R., Crockett, M. T., Alexander, L., Haran, M., Baker, A., Burke, L., Brennan, C., & O’Keane, V. (2020) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2020.94 · Cited by 16 · see citing works

A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review

Pouyan, N., Khankahdani, Z. H., Sisi, F. Y., Lee, Y. L., Rosenblat, J. D., Teopiz, K. M., Lui, L. M. W., Subramaniapillai, M., Lin, K., Nasri, F., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00944-y · Cited by 17 · see citing works

Utility of preclinical models in the study of psilocybin – A comprehensive review

Pedicini, M., & Cordner, Z. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105046 · Cited by 13 · see citing works

The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review

Pouyan, N., Sisi, F. Y., Kargar, A., Scheidegger, M., McIntyre, R. S., & Morrow, J. D. (2023) · CNS Drugs · doi:10.1007/s40263-023-01044-1 · Cited by 13 · see citing works

Psilocybin reduces alcohol self-administration via selective left nucleus accumbens activation in rats

Jeanblanc, J., Bordy, R., Fouquet, G., Jeanblanc, V., & Naassïla, M. (2024) · Brain · doi:10.1093/brain/awae136 · Cited by 13 · see citing works

Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish

Hagen, E. V., Schalomon, M., Zhang, Y., & Hamilton, T. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-54676-8 · Cited by 12 · see citing works

Less is more? A review of psilocybin microdosing

Savides, I. A., & Outhoff, K. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278769 · Cited by 12 · see citing works

The Emergence of Psilocybin in Psychiatry and Neuroscience

Omidian, H., & Omidian, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040555 · Cited by 12 · see citing works

Molecular and structural insights into the 5‐HT 2C receptor as a therapeutic target for substance use disorders

Ubhayarathna, M., Langmead, C. J., Diepenhorst, N. A., & Stewart, G. D. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16233 · Cited by 12 · see citing works

Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies

Hilal, F. F., Jeanblanc, J., Deschamps, C., Naassïla, M., Pierrefiche, O., & Hamida, S. B. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02757-3 · Cited by 8 · see citing works

Delayed Anxiolytic-Like Effects of Psilocybin in Male Mice Are Supported by Acute Glucocorticoid ReleasePreprint

Jones, N., Zahid, Z., Grady, S. M., Sultan, Z. W., Zheng, Z., Banks, M. I., & Wenthur, C. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.12.248229 · Cited by 8 · see citing works

Exploring the therapeutic potential of psychedelics in treating substance use disorders

Li, Y., Li, H., Wang, H., & Wang, X. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03168-w · Cited by 6 · see citing works

The influence of stakeholder interests on safety outcome reporting in psychedelic research and implications for science communication

Koning, E., Solmi, M., & Brietzke, E. M. (2024) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2024-0866 · Cited by 6 · see citing works

Prefrontal electrophysiological biomarkers and mechanism-based drug effects in a rat model of alcohol addiction

Habelt, B., Afanasenkau, D., Schwarz, C., Domanegg, K., Kuchař, M., Werner, C., Minev, I. R., Spanagel, R., Meinhardt, M. W., & Bernhardt, N. R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03189-z · Cited by 6 · see citing works

The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field

Syed, O. A., Petranker, R., & Tsang, B. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106204 · Cited by 6 · see citing works

Effects of pimavanserin and lorcaserin on alcohol self-administration and reinstatement in male and female rats

Fletcher, P. J., Li, Z., Ji, X., Higgins, G. A., Funk, D. R., & Lê, A. D. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109150 · Cited by 6 · see citing works

Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats

Malikowska‐Racia, N., Koniewski, M., Gołębiowska, J., & Popik, P. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231205692 · Cited by 6 · see citing works

The Therapeutic Effects of Classic Psychedelics in Alcohol Use Disorder

Pagni, B. A., Wong, J. M., & Bogenschutz, M. P. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00581-z · Cited by 5 · see citing works

Single-dose 1cp-LSD administration for canine anxiety: a pilot study

Henríquez‐Hernández, L. A., García‐Serrano, I., Hernández, D. J. Q., Rojas‐Hernández, J., Hernández‐Álvarez, E., Zumbado, M. L., Fernández‐Borkel, T., & Borkel, L. F. (2024) · Veterinary Research Communications · doi:10.1007/s11259-024-10542-6 · Cited by 5 · see citing works

Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience

Omidian, H., & Omidian, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040499 · Cited by 5 · see citing works

The utility of 2,5-dimethoxy-4-iodoamphetamine for the study of serotonin 2A and 2C receptors

Cameron, L. P., Jaster, A. M., Ramos, R., & Ullman, E. Z. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100093 · Cited by 3 · see citing works

Psilocybin administered following extinction sessions does not affect subsequent cocaine cue reinstatement in male and female rats and mice

Pohořalá, V., Kuchař, M., Spanagel, R., & Bernardi, R. E. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.09.006 · Cited by 3 · see citing works

Replikationskrise in der präklinischen Suchtforschung und Vorschläge zur Krisenbewältigung

Spanagel, R. (2021) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000722 · Cited by 3 · see citing works

Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping ReviewPreprint

Shore, R., Dobson, K., Thomson, N., Barnim, N., Bergman, H. P., Rideout, K., McKeown, S., Olmstead, M. C., Goldie, C. E., & Dumont, É. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.04.574146 · Cited by 3 · see citing works

Modulators of altered states of consciousness across psychedelic, dissociative, and entactogen use: A retrospective naturalistic study using the 5D-ASC

Romeo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Mathieu, P., Amirouche, A., Bezo, A., Hacquet, R., Piolino, P., & Benyamina, A. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111621 · Cited by 2 · see citing works

Established sensitization of ethanol-induced locomotor activity is not reversed by psilocybin or the 5-HT2A receptor agonist TCB-2 in male DBA/2J mice

Fletcher, P. J., Li, Z., Ji, X. D., & Lê, A. D. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173703 · Cited by 3 · see citing works

Letter to the editor: Comments on ‘Striking long-term beneficial effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming’ by Brownstien et al. (2024)

Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03005-0 · Cited by 2 · see citing works

Short- and Long-Acting Psychedelics: Structure–Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics

Bhat, A., Zolali, E., Sakib, M. A., Rahimian, M., McMahon, L. R., German, N., & Obeng, S. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00202 · Cited by 1 · see citing works

Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models

Ezeaka, U. C., Kim, H. J. J., & Laprairie, R. B. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230705151922 · Cited by 1 · see citing works

The Therapeutic Efficacy of Psilocybin in a Preclinical Model of Depressive- and Anxiety-Like Symptomology

Chafee, H. (2022) · doi:10.26686/wgtn.19579795

Psilocybin in the Management of Substance Use Disorders: A Summary of Current Evidence

Bourji, H. E., Farhat, A., Hamdan, Z., Satodiya, R. M., Shukla, R., & Hayek, S. E. (2024) · Current Psychopharmacologye · doi:10.2174/0122115560288779240628043307

Exploring psilocybin’s role in mental health and palliative medicine: a path to improved well-being

Umbacia, M. A., León, M., Quintero, J.-M., Castro, L.-M., Páez, V., Dodd, S., & Bustos, R. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2488786

Behavioural investigations of psilocybin in non-human animals 1962–2021: A scoping review

Shore, R., Dobson, K., Thomson, N., Barnim, N., Bergman, H. P., Rideout, K., McKeown, S., Olmstead, M. C., Goldie, C. E., & Dumont, É. C. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00364

Psychedelics for the Treatment of Substance Use Disorder

Fumàs, B., Pubill, D., López‐Arnau, R., & Nadal‐Gratacós, N. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1012870

Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping ReviewPreprint

Suspène, J., Huet, S., Berteina‐Raboin, S., Benyamina, A., Baril, P., Morisset‐Lopez, S., & Serreau, R. (2025) · Qeios · doi:10.32388/xcfsag

Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping ReviewPreprint

Suspène, J., Huet, S., Berteina‐Raboin, S., Benyamina, A., Baril, P., Morisset‐Lopez, S., & Serreau, R. (2025) · Qeios · doi:10.32388/xcfsag.2

Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency

Hosford, S., & Austin-Robillard, H. (2025) · Contemporary Family Therapy · doi:10.1007/s10591-025-09766-8

Microdoses de psicodélicos no tratamento de transtornos mentais: uma revisão sistemática

Cavalcante, G. J. C. S., Magrini, A. T., Rigelli, R. H., Dendasck, C. V., Dias, C. A. G. D. M., de Araújo, M. H. M., & Fecury, A. A. (2025) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/saude/microdoses-de-psicodelicos

The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing

Page, J., Moore, A., Hawkins, B. E., Lyons, E., & Lorenzo, E. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1866881

MDMA administration reduces ethanol drinking and is associated with altered nociceptin and dynorphin system gene expression in alcohol-preferring rats

Rullo, L., Losapio, L. M., Mrizak, H., Morosini, C., Nasuti, C., Ubaldi, M., Mangione, P., Lacorte, A., Coluzzi, F., Soverchia, L., et al. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111187

Preclinical Phase II Testing of Psilocybin and LSD in Alcohol Addiction

Meinhardt, M. (2020) · Bundesinstitut für Risikobewertung Fachgruppe ZEBET - Datenbank und Informationsbeschaffung Abteilung Experimentelle Toxikologie und ZEBET · doi:10.17590/asr.0000216

Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories

Benvenuti, F., Colombo, D., Soverchia, L., Cannella, N., Domi, E., & Ciccocioppo, R. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06384-w · Cited by 18 · see citing works

Psychedelics as treatment of alcohol use disorders: insights from preclinical models and comparison of the different psychedelics psilocybin, LSD and ketamine

Naassïla, M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.05.064

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103149 · Cited by 61 · see citing works

Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats

Reinwald, J., Schmitz, C. N., Skorodumov, I., Kuchař, M., Weber‐Fahr, W., Spanagel, R., & Meinhardt, M. W. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02690-1 · Cited by 25 · see citing works